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Abstract
Background: In this study, we evaluated the impact of obesity and/or overweight on the achievement of minimal
disease activity (MDA) in patients with psoriatic arthritis (PsA) and patients with rheumatoid arthritis (RA) receiving
an anti-rheumatic treatment. Obesity can be considered a low-grade, chronic systemic inflammatory disease and
some studies suggested that obese patients with rheumatic diseases exhibit a lower rate of low disease activity
achievement during treatment with anti-rheumatic drugs.
Methods: A systematic search was performed in major electronic databases (PubMed, Web of Science, Scopus,
Embase) to identify studies reporting MDA achievement in obese and/or overweight patients with RA or PsA and in
normal-weight RA or PsA control subjects. Results were expressed as Odds Ratios (ORs) with pertinent 95%
Confidence Intervals (95%CIs).
Results: We included 17 studies (10 on RA and 7 on PsA) comprising a total of 6693 patients (1562 with PsA and
5131 with RA) in the analysis. The MDA achievement rate was significantly lower in obese patients than in normal-
weight subjects (OR 0.447, 95% CI 0.346–0.577, p < 0.001, I2 = 62.6%, p < 0.001). Similarly, overweight patients
showed a significantly lower prevalence of MDA achievement than normal-weight subjects (OR 0.867, 95% CI 0.
757–0.994, p = 0.041, I2 = 64%, p = 0.007). Interestingly, the effect of obesity on MDA was confirmed when we
separately analyzed data on patients with RA and patients with PsA. In contrast, when we evaluated the effect of
overweight, our results were confirmed for PsA but not for RA. A meta-regression analysis showed that follow-up
duration, age, male sex, and treatment duration are covariates significantly affecting the effect of obesity/
overweight on MDA achievement.
Conclusions: The results of our meta-analysis suggest that obesity and overweight reduce the chances to achieve
MDA in patients with rheumatic diseases receiving treatment with traditional or biologic disease-modifying
antirheumatic drugs.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by inflammation of the synovial tissue
that leads to bone erosion and progressive disability. Its
prevalence of 0.5–1% in the general population makes it
the most common chronic inflammatory condition [1].
Psoriatic arthritis (PsA) is a chronic inflammatory joint
disease affecting up to 40% of patient with psoriasis, with
a prevalence of 0.3–1% in the general population and lead-
ing to severe physical limitations and disabilities [2].
Besides articular manifestations, PsA and RA are charac-
terized by an increased cardiovascular (CV) risk [3, 4], as
represented by a higher prevalence of metabolic syndrome
and of some of its major features (obesity, hypertension,
hypercholesterolemia, hypertriglyceridemia, impaired fast-
ing glucose) [5], increased platelet reactivity [6–8], higher
degree of subclinical atherosclerosis [4, 9], impairment of
endothelial function, and arterial stiffness [10–12]. In par-
ticular, several studies have shown a higher prevalence of
obesity in patient with PsA and patients with RA than in
the general population. Obesity causes an abnormal expres-
sion of adipokines (e.g., tumor necrosis factor-α [TNF-α],
interleukin-6 [IL-6], adiponectin, leptin), which leads to a
proinflammatory status. Thus, obesity can be considered a
low-grade, chronic systemic inflammatory disease [13, 14].
Moreover, immune-mediated inflammation may act syner-
gistically with obesity-mediated inflammatory status and
may influence disease activity in rheumatic diseases [13, 15,
16]. Some studies [17] suggested that obese patients with
rheumatic diseases exhibit a lower rate of low disease activ-
ity achievement during treatment with antirheumatic drugs.
However, these results were challenged and not confirmed
by other studies [18, 19]. In the present meta-analysis, we
evaluated whether obesity and overweight impact the clin-
ical response in patients with PsA and patients with RA re-
ceiving treatment with traditional disease-modifying
antirheumatic drugs (DMARDs) or biologic DMARDs.
Methods
A protocol for this review was prospectively developed,
detailing the specific objectives, the criteria for study se-
lection, the approach to assessment of study quality, the
outcomes, and the statistical methods.
Search strategy
To identify all available studies, a detailed search of studies
reporting the achievement of minimal disease activity (MDA)
in obese/overweight patients with RA/PsA and in normal-
weight control subjects was conducted according to Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) guidelines [20]. A systematic searchwas performed
in major electronic databases (PubMed,Web of Science, Sco-
pus, Embase), using the following search terms in all possible
combinations: psoriatic arthritis, rheumatoid arthritis, obese,
obesity, overweight, body mass index, body composition, body
weight, adiposity. The latest search was performed in June
2016. The search strategy was developed without any lan-
guage or publication year restriction. In addition, the reference
lists of all retrieved articles were manually reviewed. In case of
missing data, study authors were contacted by email to try to
retrieve original data. Two independent authors (RL and PP)
analyzed each article and performed the data extraction inde-
pendently. In case of disagreement, a third investigator was
consulted (MNDDM). Discrepancies were resolved by con-
sensus. Selection results are reported according to a PRISMA
flowchart (Additional file 1).
Data extraction and quality assessment
According to the prespecified protocol, all studies comparing
the rate ofMDA achievement in obese or overweight patients
with RA or PsA and in normal-weight control subjects were
included. Case reports, animal models, and reviews were ex-
cluded. To be included in the analysis, a study had to provide
the rate of MDA achievement in obese and/or in overweight
patients with RA and/or PsA versus normal-weight control
subjects. Also, studies reporting theORwith 95%CI forMDA
achievement between obese or overweight patients with RA
or PsA and normal-weight control subjects were included.
Obesity and overweight were defined according to BMI cat-
egories of included patients: normal weight (BMI <25 kg/m2),
overweight (BMI 25–30 kg/m2), and obese (BMI >30 kg/m2).
MDA achievement was defined on the basis of Disease Activ-
ity Score in 28 joints (DAS28) or according to Coates criteria
during treatment. From each study, data regarding sample
size, major clinical and demographic variables, and data about
MDA achievement were extracted. To exclude the risk of data
overlap, original databases were analyzed for studies per-
formed in the same institutions. Evaluation of methodological
quality of each study was not performed, because it failed to
demonstrate a clear advantage [21].
Statistical analysis and risk of bias assessment
Statistical analysis was carried out using Comprehensive
Meta-analysis version 2 software (2005; Biostat, Englewood,
NJ, USA). Differences inMDA achievement between obese or
overweight patients with RA or PsA and normal-weight con-
trol subjects were expressed as ORs with pertinent 95% CIs.
The overall effect was tested using Z-scores, and significance
was set at p < 0.05. Furthermore, meta-regression analysis was
performed to evaluate the impact of clinical and demographic
data on the evaluated outcomes.
Statistical heterogeneity between studies was assessed with
chi-square test or Cochran’s Q test, and the I2 statistic, which
measures inconsistency across study results and describes
the proportion of total variation in study estimates that is
due to heterogeneity rather than sampling error. In detail, I2
values of 0% indicate no heterogeneity, 25% low heterogen-
eity, 25–50% moderate heterogeneity, and 50% high
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heterogeneity [22]. Publication bias was represented graphic-
ally by funnel plots of the standard difference in means ver-
sus the standard error. Visual inspection of funnel plot
asymmetry was performed to address possible small-study
effect [23]. In order to be as conservative as possible, the
random-effect method was used to take into account the
variability among included studies.
Subgroup analyses
We also planned to perform subanalyses of results accord-
ing to the type of rheumatic disease evaluated (RA or PsA).
Sensitivity analyses
Given the several confounding factors that might impact
the difference in MDA achievement between obese or
overweight patients and normal-weight control subjects, a
sensitivity analysis was performed by pooling only ORs of
MDA achievement obtained by means of multivariate ana-
lysis and adjusted for a series of potential confounders. In
addition, a further sensitivity analysis was performed after
excluding studies defining obesity as BMI >25 kg/m2 and
the study defining MDA as an on-treatment DAS28 < 5.1.
Meta-regression analyses
We hypothesized that differences among included studies
might be affected by demographic (mean age, male sex) and
clinical (follow-up duration, treatment duration, baseline
DAS28, disease duration, C-reactive protein [CRP] and
erythrocyte sedimentation rate [ESR] at baseline) variables.
To assess the possible effect of such variables in explaining dif-
ferent results observed across studies, we planned to perform
meta-regression analyses after implementing a regression
model with MDA achievement as a dependent variable (y)
and the above-mentioned covariates as independent variables
(x). This analysis was performed with Comprehensive Meta-
analysis version 2 software.
Results
As reported in Additional file 1: Figure S1, of the 603 re-
trieved studies, 583 were excluded because they were re-
views or case reports or were judged to be off the topic after
scanning the title and/or the abstract. Another three studies
were excluded after full-length paper evaluation because they
reported only data about radiographic joint damage progres-
sion. Thus, 17 studies [7, 15–19, 24–34] (10 on RA and 7 on
PsA) comprising a total of 6693 patients (1562 with PsA and
5131 with RA) were included in the analysis. All the in-
cluded studies stratified the study population according to
the presence of obesity. In addition, eight studies [17–19,
29–33] also reported data on overweight patients.
Study characteristics
The major characteristics of included studies are shown
in Table 1. With the exception of three studies in which
researchers defined obesity as a BMI >25 kg/m2 [18, 27,
28], patients were categorized into the following groups
according to their body mass index (BMI): normal
(<25 kg/m2), overweight (25–30 kg/m2), and obese
(>30 kg/m2). Overall, a total of 1765 (26.4%) of 6693 en-
rolled patients were obese, 1579 (23.6%) were over-
weight, and 3349 (50.0%) were normal weight.
The mean age of the subjects ranged from 45.6 to
64.6 years, the prevalence of male sex from 11.3% to 58.7%,
and the treatment duration from 3 to 42.6 months. The
cutoffs used to define achievement of MDA were based on
an on-treatment DAS28 score <2.6 in seven studies [17, 18,
25, 28, 29, 33, 34], <5.1 in one study [32], or according to
the Coates criteria in six studies [7, 15, 16, 19, 24, 30].
MDA and body weight
All the 17 studies [7, 15–19, 24–34] provided data about
achievement of MDA in 1765 obese patients with PsA or
RA receiving a treatment with traditional or biologic
DMARDs. As showed in Fig. 1, the remission rate was sig-
nificantly lower in the 1765 obese patients than in the 3349
normal-weight subjects (30.9%, [95% CI 21.1–42.8%] vs.
50.0% [95% CI 38.8–61.1%]) with a corresponding OR of
0.447 (95% CI 0.346–0.577, p < 0.001, I2 = 62.6%, p < 0.001).
The heterogeneity was not reduced by the exclusion of one
study at a time. Overall, the risk of not achieving MDA at-
tributable to the presence of obesity was 38.2%.
Interestingly, a significant difference was also found in
eight studies [17–19, 29–33] in which researchers reported
data on overweight patients and showed a significantly lower
prevalence of MDA achievement in the 1579 overweight pa-
tients (297 with PsA and 1282 with RA) than in the 1794
normal-weight subjects (OR 0.867, 95% CI 0.757–0.994, p=
0.041, I2 = 64%, p= 0.007) (Fig. 2). The heterogeneity was
not reduced by the exclusion of one study at a time.
Subgroup analyses (PsA and RA)
As shown in Table 2, 10 of the 17 studies [18, 25–29,
31–34] included in our meta-analysis enrolled patients
with RA, whereas the remaining 7 [7, 15–17, 19, 24, 30]
examined patients with PsA. Overall, the studies on pa-
tients with RA comprised a total of 3849 patients, in-
cluding 1122 obese subjects compared and 2727
normal-weight control subjects. The studies on PsA
comprised a total of 1265 patients, including 643 obese
subjects and 622 normal-weight control subjects. The
MDA achievement rate was significantly higher in those
who had a normal body weight than in obese patients,
both in patients with RA (OR 0.583, 95% CI 0.401–
0.848, p = 0.005) and in those with PsA (OR 0.369, 95%
CI 0.249–0.546, p < 0.001). In contrast, when we evalu-
ated the effect of overweight, we found that these results
were confirmed for PsA but not for RA (Table 2).
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Sensitivity analyses
To minimize the impact of several confounding factors
on the difference in MDA achievement between obese
or overweight patients and normal-weight control sub-
jects, we pooled data from the five studies [18, 19, 25,
27, 34] in which researchers reported adjusted risk esti-
mates. This sensitivity analysis consistently confirmed
the lower MDA achievement, both in obese (OR 0.481,
95% CI 0.385–0.602) and in overweight patients (OR
0.657, 95% CI 0.521–0.829), than in normal-weight con-
trol subjects. In addition, these results were confirmed
after we excluded studies [18, 27, 28] defining obesity as
BMI >25 kg/m2 and the study [32] defining MDA as an
on-treatment DAS28 < 5.1 (Additional file 1: Figure S2).
Publication bias
Funnel plots of effect size versus standard error for stud-
ies evaluating the association of BMI with MDA rate
were quite symmetrical, suggesting absence of publica-
tion bias and of small-study effect (Additional file 1: Fig-
ure S3). Egger’s test confirmed the absence of
publication bias both for studies on obesity (p =0.285)
and for studies on overweight (p = 0.314).
Meta-regression analysis
To further assess the impact of BMI on decreasing
chances of remission, some meta-regression analyses
were performed. While follow-up, age, male sex, and
treatment duration affected the difference in MDA
achievement between obese or overweight patients and
normal-weight subjects (Z-value 2.66, p = 0.008; Z-value
3.19, p = 0.001; Z-value −2.29, p = 0.022; Z-values 3.0, p
= 0.003, respectively) (Fig. 3), baseline DAS28, disease
duration, CRP, and ESR at baseline did not (Z-value
−0.22, p = 0.827; Z-value −1.08, p = 0.277, Z-value −1.60,
p = 0.108; and Z-value 1.62, p = 0.104, respectively)
(Additional file 1: Figure S4).
Discussion
In the present meta-analysis, we evaluated the impact of
obesity or overweight on the achievement of MDA in
patients with PsA and patients with RA receiving treat-
ment with traditional or biologic DMARDs. We found a
significantly lower MDA achievement in obese patients
(BMI >30 kg/m2) than in those with a normal weight
(BMI <25 kg/m2). Interestingly, a significant difference
has been also documented in overweight patients (BMI

























524 (39.3) 30.8 64.6 – – 0.4 13
Choe, 2014 [28] RA 568 108
(19.0)
– 11.3 56.6 85.2 – 0.07 31.2
Di Minno, 2012 [3] PsA 270 111
(41.1)
– 45.9 51.73 58.44 12 0.264 18.05
Di Minno, 2012 [6] PsA 90 29 (32.2) – 46.7 52.5 108.96 12 0.22 17.9
Di Minno, 2013
[15]
PsA 270 135 (50) – 46 51.7 110.9 12 2.6 18.1
Di Minno, 2014 [5] PsA 76 44 (57.9) – 43.6 46.2 114 6 0.42 20.2
Eder, 2015 [19] PsA 557 197
(35.4)
200 (35.9) 58.7 52.1 138 12 1.49 20.3
Ellerby, 2014 [25] RA 233 57 (24.5) – 30.9 60.8 129.6 36 – –
Gremese, 2013 [29] RA 641 66 (10.3) 207 (32.3) 18.7 52.1 100.8 12 – 35.9
Heimans, 2013 [27] RA 508 292
(57.5)
– 32.6 54.7 – 12 2.06 35.7
Iannone, 2013 [17] PsA 135 45 (33.3) 47 (34.8) 50.4 53.2 120 42.6 1.5 25.6
Iannone, 2015 [26] RA 292 66 (22.6) – 14.8 57.9 146.4 12 2,2 37.4
Iervolino, 2012 [30] PsA 136 82 (60.3) 50 (36.8) 42.6 45.62 62.28 3 0.602 21.93
Klaasen, 2011 [31] RA 89 15 (16.9) 66 (74.2) 25.9 55.7 98.9 4 2.27 34.7
Rodrigues, 2014
[34]
RA 317 73 (23.0) – – – – 6 – –
Sandberg, 2014
[18]
RA 495 85 (17.2) 170 (34.3) 28.7 – 6 6 – –
Westhoff, 2007 [32] RA 767 149
(19.4)
315 (41.1) 28.4 57.2 11.5 36 2.15 –
Abbreviations: RA rheumatoid arthritis, PsA psoriatic arthritis, CRP C reactive protein, ESR erythrocyte sedimentation rate
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from 25 to 30 kg/m2) compared with those with a nor-
mal weight (BMI <25 kg/m2). Moreover, all results were
confirmed when we separately analyzed patients with
RA and patients with PsA.
Meta-regression analyses refined and extended our
findings. Interestingly, we found that follow-up, treat-
ment duration, age, and male sex affected the difference
in MDA achievement between obese patients and
normal-weight subjects. In detail, we found that a pro-
gressive increase in treatment duration leads to a lower
difference in the rate of MDA achievement between
obese patients and those with a normal weight. This re-
sult might suggest that obese patients may need a
longer-lasting antirheumatic treatment to achieve MDA.
However, data about the time needed to achieve MDA
are not available; thus, further studies with ad hoc de-
signs are needed to verify this hypothesis.
With regard to age and sex, we found that the reduc-
tion in MDA achievement due to obesity is more
significant in males and in younger subjects. This finding
is of particular interest, considering that some previous
data suggested that a young age and male sex are able to
identify patients most likely to achieve MDA during
treatment with antirheumatic drugs [30, 35]. Thus, ac-
cording to our results, obesity could hamper the effect
of these predictors of MDA achievement. However, these
results could be due to chance, and further studies
evaluating potential underlying mechanisms are needed
to address this issue.
Several different mechanisms may be involved in the
explanation of the impact of obesity on MDA achieve-
ment. It is known that adipose tissue has an endocrine
function because it secretes many molecules (adipo-
kines) involved in the inflammatory network. These me-
diators include mainly adiponectin, leptin, plasminogen
activator inhibitor-1 (PAI-1), IL-6, and TNF-α. Adipo-
nectin is an anti-inflammatory cytokine. A low concen-
tration of adiponectin is associated with insulin
Fig. 2 Forest plot of minimal disease activity achievement in overweight patients versus normal-weight patients with rheumatic diseases
(rheumatoid arthritis or psoriatic arthritis)
Fig. 1 Forest plot of minimal disease activity achievement in obese patients versus normal-weight patients with rheumatic diseases (rheumatoid
arthritis or psoriatic arthritis)
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resistance and impaired endothelium-dependent vaso-
dilation. Low serum levels of adiponectin have been re-
ported in several chronic diseases such as obesity and
psoriasis. Both leptin and PAI-1 induce endothelial dys-
function. In addition, IL-6 and TNF-α promote insulin
resistance in skeletal muscle and liver as well as proin-
flammatory activity in synovial tissue. Moreover, TNF-α
induces endothelial dysfunction and liver synthesis of
clotting factors, thus predisposing individuals to athero-
sclerosis and atherothrombosis [36]. High levels of TNF-
α and IL-6 eventually reduce adiponectin production by
adipose tissue, determining a self-maintained system.
A further relevant information that could be derived
from our study is the prevalence of obesity in patients
with rheumatic disease. Interestingly, patients were con-
secutively enrolled in the included studies, and among
6693 patients (1562 with PsA and 5131 with RA), the
prevalence of obesity or overweight was about 50%. This
finding further strengthens the hypothesis of the high
prevalence of cardiometabolic risk factors in patients
with rheumatic diseases [4, 37]. Much data in the litera-
ture supports this possibility [38–40], and the finding
that the vascular morbidity/mortality of patients with
rheumatic diseases resembles that of patients with type
Fig. 3 Meta-regression of the effect of follow-up duration, age, sex, and treatment duration on the difference in minimal disease activity achieve-
ment between obese patients and control subjects
Table 2 Odds of achieving minimal disease activity in obese patients versus normal-weight patients, stratified according to type of
rheumatic disease (rheumatoid arthritis and psoriatic arthritis)
Number of studies Population, n OR (95% CI), p value Heterogeneity (I2, p value)
Obesity vs. normal weight
Rheumatoid arthritis 10 0.583 (0.401–0.848), p = 0.005 I2 = 66.2%, p = 0.002
Obese 1122
Normal weight 2727
Psoriatic arthritis 7 0.369 (0.249–0.546), p < 0.001 I2 = 63.1%, p = 0.012
Obese 643
Normal weight 622
Overweight vs. normal weight
Rheumatoid arthritis 5 1.00 (0.849–1.182), p = 0.984 I2 = 23.7%, p = 0.263
Overweight 1282
Normal weight 1517
Psoriatic arthritis 3 0.637 (0.500–0.811), p < 0.001 I2 = 60.2%, p = 0.081
Overweight 297
Normal weight 277
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2 diabetes mellitus further helps define the severity of
the CV risk in this clinical setting [41]. In fact, obesity is
associated with a hyperexpression of TNF-α and other adipo-
kines (e.g., IL-6, leptin, adiponectin) and transforming growth
factor-β, which leads to a chronic proinflammatory state.
Moreover, subjects with rheumatic diseases exhibit an en-
hanced prevalence of the metabolic syndrome and of some
of its major features (obesity, hypertension, hypercholesterol-
emia, hypertriglyceridemia, and impaired fasting glucose).
However, such an association does not entirely explain the
extent of premature atherosclerosis in subjects with rheum-
atic diseases, and inflammation appears to act synergistic-
ally with traditional vascular risk factors (VRFs). In fact,
several studies demonstrated that patients with rheumatic
diseases had increased platelet reactivity [6–8], a higher
grade of subclinical atherosclerosis [4, 9], impairment of
endothelial function, and arterial stiffness [10–12], as
compared with control subjects matched for CV risk fac-
tors. In this setting, antirheumatic treatment was demon-
strated to have beneficial effects on lowering the CV risk
in these patients by controlling systemic inflammation,
with maximum effect in those who achieved MDA [8].
Our study has some potential limitations. First, the
studies included in our meta-analysis had different inclu-
sion and exclusion criteria, and there was significant het-
erogeneity among the studies. Interestingly, all studies
used standardized BMI cutoffs to define the presence/
absence of obesity/overweight. However, three studies
that defined obesity as a BMI >25 kg/m2 [18, 27, 28] did
not provide separate data for overweight and obesity.
Interestingly, when we repeated the analyses after ex-
cluding these three studies, all results were entirely con-
firmed. A further potential source of bias is the lack of
data about changes in BMI during the study period.
Some evidence in the literature suggested that treatment
with antirheumatic drugs is able to modify BMI [3, 42]
and that weight loss is able to increase the MDA
achievement rate [5]. This should be taken into account
when interpreting results of the present meta-analysis.
The definition of MDA was highly variable among
studies. The cutoff to define MDA achievement was
based on an on-treatment DAS28 score <2.6 in seven
studies [17, 18, 25, 28, 29, 33, 34], <5.1 in one study
[32], and according to the Coates criteria in six studies
on PsA [7, 15, 16, 19, 24, 30]. In addition, both DAS28
and Coates criteria also include ESR and CRP values for
the assessment of disease activity. Because obesity is as-
sociated with low-grade inflammation [13], ESR and
CRP levels can result in elevated independently of dis-
ease activity. This may lead to a misclassification of
MDA achievement. To overcome this problem, newer
criteria for MDA definition, specific for obese patients
and independent of ESR and CRP, should be used in fu-
ture studies. Furthermore, there are some major
differences in the prevalence of clinical and demographic
data of enrolled patients, and, with the meta-regression
approach, we were able to adjust results for some but
not all potential confounders. Thus, extreme caution is
necessary in interpretation of the overall results.
Although it was not possible to conclusively ascertain
sources of heterogeneity, all results were confirmed in all
subgroups and sensitivity analyses, and no publication bias
was found in our analyses. Moreover, to take into account
the effect of confounding factors on the difference in the
MDA achievement between obese or overweight patients
and normal-weight control subjects, we repeated the ana-
lysis by pooling only data adjusted for potential con-
founders, and all results were confirmed. Differences in the
types of rheumatic disease studied might represent a poten-
tial source of bias. In particular, 10 of the 17 studies in-
cluded in our meta-analysis were performed with patients
with RA, whereas the remaining 7 studies were of patients
with PsA. Interestingly, the results obtained in the primary
analysis were entirely confirmed when we separately ana-
lyzed data on PsA and RA.
Conclusions
Despite some limitations, the results of our study sug-
gest that obesity and overweight reduce the chances to
achieve MDA in patients with rheumatic diseases start-
ing treatment with antirheumatic drugs.
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